US Earnings Financial Results SEC Filings — March 05, 2026

05-03-2026

05-03-2026

Ferrellgas Partners, L.P. reported Q2 FY2026 (three months ended Jan 31, 2026) revenues of $641.4M, down 4.2% YoY from $669.8M due to lower propane sales (-5.4%), though other revenues rose 21%; operating income increased 6.6% to $136.2M and net earnings grew 3.4% to $103.1M. For the six months ended Jan 31, 2026, revenues declined 3.6% YoY to $997M but the company swung to net earnings of $75.7M from a $48.6M loss, driven by lower cost of propane sales (-8.2%) and sharply reduced G&A expenses (-85%); however, interest expense rose 11% to $59.8M amid higher debt. Total assets expanded 9% sequentially to $1.54B at Jan 31, 2026 from $1.42B at Jul 31, 2025, but long-term debt surged 78% to $1.45B following refinancing, while cash fell to $88M from $97M.

• ·Allowance for expected credit losses increased to $4.98M from $4.33M sequentially.
• ·Short-term borrowings initiated at $62.5M (none at Jul 31, 2025).
• ·Current portion of long-term debt dropped sharply to $1.7M from $652M (refinancing effect).
• ·Net cash used in investing activities $43M for 6M (flat YoY).
• ·Proceeds from long-term debt issuance $650M; payment for settlement/early extinguishment $650M in financing activities.

05-03-2026

CrowdStrike reported FY26 total revenue of $4.81B, up 22% YoY from $3.95B, driven by 21% growth in subscription revenue to $4.56B and 29% in professional services to $0.25B, with ARR reaching $5.25B (24% YoY growth). However, the company posted a net loss attributable to CrowdStrike of $162.5M, wider than the $15.2M loss in FY25, as operating expenses surged 26% to $3.89B, outpacing revenue growth and leading to an operating loss of $293M (vs. $116M prior year). Gross margins remained flat at 75%, while sales & marketing, R&D, and G&A expenses rose 20%, 29%, and 39% YoY, respectively.

• ·Subscription represented 95% of total revenue in FY26, flat YoY.
• ·Professional services gross margin declined 1pp to 18% in FY26.
• ·Provision for income taxes was $34.2M in FY26, down from $71.1M in FY25.

05-03-2026

Enhabit, Inc. reported consolidated net service revenue of $1.06B for the year ended December 31, 2025, up 2.4% YoY from $1.03B, driven by strong Hospice segment growth of 17.2% to $246M, while Home Health revenue declined 1.3% to $814M due to a 6.1% drop in Medicare revenue. Adjusted EBITDA improved 8.4% YoY to $109M with Hospice Adjusted EBITDA surging 44.1% to $60M, but Home Health Adjusted EBITDA fell 6.8% to $149M; net loss attributable to Enhabit narrowed 97.1% to $(4.6)M from $(156M), though impairments totaled $48M including $45M goodwill.

• ·Medicare Home Health admissions declined 5.1% YoY to 91,603 in 2025.
• ·Home Health visits per episode decreased 5.6% YoY to 13.4.
• ·Cost per visit in Home Health rose 5.1% YoY to $97.7.
• ·Depreciation and amortization dropped 28.6% YoY to $22.5M.
• ·Interest expense decreased 20.7% YoY to $34.0M.

05-03-2026

Hippo Holdings Inc. reported total revenue of $468.6M for the year ended December 31, 2025, up 26% YoY from $372.1M, primarily driven by net earned premium growth of 39% to $380.1M and gross written premium increasing to $1,108.6M from $892.4M. The company achieved net income attributable to Hippo of $57.7M, reversing a $40.5M loss in 2024, with net loss ratio improving to 60% from 77% and combined ratio to 113% from 138%; however, insurance related expenses surged 48% to $131.3M, losses and loss adjustment expenses rose 10% to $229.9M, and commission income declined 19% to $51.3M.

• ·Book value per share increased to $16.97 in 2025 from $14.56 in 2024.
• ·Diluted adjusted earnings per share improved to $0.68 in 2025 from ($0.82) in 2024.
• ·Adjusted net income was $17.8M in 2025, compared to ($20.3M) loss in 2024.
• ·Catastrophe losses $61.5M in 2025 vs $58.0M in 2024 (up 6%).
• ·Non-catastrophe loss ratio improved to 45% in 2025 from 56% in 2024.

05-03-2026

STEM, Inc. reported FY2025 revenue of $156.3M, up 8% YoY from $144.6M, driven by 29% growth in services and other revenue to $87.7M, though hardware revenue declined 11% to $68.6M. The company achieved GAAP net income of $137.8M versus a $854.0M loss in 2024, aided by a $220M gain on debt extinguishment and GAAP gross profit of $60.0M (38% margin) versus a $11.1M loss (-8% margin); however, it posted an operating loss of $55.7M, Adjusted EBITDA of $6.7M remained modest, and storage operating AUM fell slightly to 1.7 GWh from 1.8 GWh. Bookings rose 14% to $131.8M, CARR increased 4% to $67.2M, but total assets decreased to $308.9M from $437.4M amid metric redefinitions impacting comparability.

• ·Net cash provided by operating activities improved to $6.9M in FY2025 from ($36.7M) used.
• ·Convertible notes noncurrent decreased to $183.6M from $525.9M; senior secured notes added at $128.8M.
• ·Several key operating metrics (Bookings, Contracted backlog, CARR) redefined starting Q1 2025 to focus on executed purchase orders, reducing prior comparability.
• ·Cash and equivalents $48.9M at Dec 31, 2025, down from $56.3M.

05-03-2026

StubHub Holdings, Inc. reported revenue of $1.75B for the year ended December 31, 2025, a slight decline of 1.4% YoY from $1.77B in 2024. However, the company swung to a massive net loss of $1.91B from a near-breakeven loss of $2.8k in 2024, driven by general and administrative expenses surging to $1.71B (including $1.45B in stock-based compensation) from $387M. While cost of revenue decreased 6% and interest expense fell 22.1%, sales and marketing expenses rose 17.4% YoY.

• ·Operations and support expenses increased to $63.2M in 2025 from $59.5M in 2024.
• ·Loss from operations was $1.34B in 2025 versus income of $138M in 2024.
• ·Foreign currency losses of $89.7M in 2025 compared to gains of $41.1M in 2024.
• ·Revenue grew 27.6% from 2023 to 2024 but declined 1.4% in 2025.

05-03-2026

Palladyne AI Corp. reported net revenue of $5.2M for the year ended December 31, 2025, down 33% YoY from $7.8M, with services revenue declining 9% to $4.7M, product revenue plummeting 100% to $3k, offset partially by new manufacturing revenue of $0.6M. Operating expenses increased 8% to $37.7M, widening the operating loss to $32.4M from $26.9M, but a $37.7M gain on warrant liabilities (versus a $46.9M loss prior year) drove net income of $10.0M compared to a $72.6M loss in 2024. Cash and equivalents fell 42% to $18.2M from $31.2M, with net cash used in operations up 22% to $27.6M.

• ·Warrant liabilities decreased to $2.8M from $51.4M as of Dec 31 2025.
• ·Total assets grew to $95.7M from $56.3M, driven by $28.8M marketable securities and new goodwill $14.7M.
• ·Stockholders' equity turned positive at $74.7M from deficit of $9.5M.
• ·Accounts receivable allowance for credit losses $0.0M in 2025 vs $0.3M in 2024.

05-03-2026

Shattuck Labs, Inc. reported total revenue of $1M for the year ended December 31, 2025, down 82.5% from $5.7M in 2024 primarily due to the absence of $5.7M in collaboration revenue. Research and development expenses decreased 47.5% to $35.3M, while general and administrative expenses fell 9.7% to $17.2M, resulting in a narrower net loss of $48.8M (35.3% improvement) compared to $75.4M in 2024. Cash and equivalents ended at $54.2M after a modest $3.2M decrease, bolstered by $44.6M in financing activities from stock sales.

• ·Cash and equivalents decreased $3.2M to $54.2M in 2025 vs $68.2M decrease to $57.4M in 2024.
• ·Shares outstanding increased to 63.3M from 47.7M due to $44.5M stock offering.
• ·Total assets stable at $91.0M; stockholders' equity rose to $82.4M from $79.6M.
• ·Net cash used in operating activities improved to $39.9M from $60.5M.

05-03-2026

CPI Card Group Inc. (PMTS) reported FY 2025 revenue of $543.5M, up 13.1% YoY from $480.6M, driven by segment revenue growth of 20.3% to $451.5M. However, gross profit declined 0.7% to $170.1M with margin compression to 31.3% from 35.6%, operating income fell 12.7% to $54.8M, and net income dropped 23.4% to $15.0M amid higher COGS (+20.7%) and SG&A (+6.3%). Segment operating income was nearly flat, down 1.5% to $91.4M, with gross margin slipping to 30.6%.

• ·Gross profit margin declined to 31.3% in FY 2025 from 35.6% in FY 2024.
• ·Segment gross profit margin declined to 30.6% in FY 2025 from 34.1% in FY 2024.
• ·Risk factors include debt service obligations limiting cash flow for working capital, R&D, capex, and acquisitions; exposure to floating rate revolving credit facility and potential higher interest rates.

05-03-2026

Liquidia Corp (LQDA) reported total revenue of $158.3M for the year ended December 31, 2025, surging 1,031% YoY to $158.3M from $14.0M in 2024, driven by $148.3M in new product sales (primarily YUTREPIA and Treprostinil Injection) while service revenue declined 28% to $10.0M. However, selling, general, and administrative expenses rose 93% to $157.2M, contributing to total costs up 55% and an operating loss of $51.4M (improved 58% YoY); net loss narrowed 46% to $68.9M but cash used in operations remained high at $35.7M. The company faces commercialization risks, covenant restrictions from its HCR financing facility, and potential need for additional capital.

• ·Net cash provided by investing activities: $(6.3M) in 2025 vs. $(8.4M) in 2024.
• ·Net increase in cash, cash equivalents, and restricted cash: $17.7M in 2025 vs. $92.8M in 2024.
• ·Financing activities provided $194.7M in 2024, down to $59.7M in 2025.

05-03-2026

Myers Industries Inc reported FY2025 total net sales of $825.7M, down 1.3% YoY from $836.3M, driven by a flat Material Handling segment at $622.1M (up 0.1%) and a 5.1% decline in Distribution to $203.9M. Gross profit rose 1.9% to $276.1M with margin expansion to 33.4% from 32.4%, while SG&A expenses fell 0.9% to 20.9% of sales, resulting in income before taxes surging to $45.1M from $13.5M. Net interest expense decreased 4.9% amid lower borrowing rates.

• ·Average outstanding borrowings increased 2.7% YoY to $391.5M.
• ·Multiple leased facilities with expirations through 2036.
• ·Audited by Ernst & Young LLP.

05-03-2026

Tango Therapeutics, a precision oncology company with no approved products or product sales revenue, reported total revenue of $62.4M for the year ended December 31, 2025, up 48% YoY from $42.1M driven by collaboration revenue, though license revenue fell to $0 from $12.1M. Operating expenses declined 7% YoY to $173.7M, narrowing the net loss to $101.6M from $130.3M; however, net cash used in operating activities increased to $138.9M from $131.5M. Cash, equivalents, and marketable securities totaled $343.1M, sufficient to fund operations into 2028.

• ·Existing cash, cash equivalents, and marketable securities to fund operations into 2028
• ·Common stock authorized increased to 400M shares at Dec 31 2025 from 200M at Dec 31 2024
• ·Accumulated deficit increased to $603.2M at Dec 31 2025 from $501.6M at Dec 31 2024
• ·Total stockholders’ equity grew to $346.2M at Dec 31 2025 from $199.5M at Dec 31 2024

05-03-2026

Climb Bio, Inc. reported a narrowed net loss of $59.9M for the year ended December 31, 2025, an improvement of 19% YoY from $73.9M, driven by the absence of a $51.7M acquired in-process R&D charge and a 17% decline in total operating expenses to $67.9M. However, R&D expenses surged 226% YoY to $46.7M amid increased investment, net cash used in operating activities more than tripled to $54.4M, and cash and equivalents dropped 59% to $35.7M, contributing to a 23% reduction in total assets to $167.7M.

• ·Common shares outstanding decreased to 47.8M from 67.3M due to exchange for pre-funded warrants.
• ·Accumulated deficit increased to $289.7M from $229.9M.
• ·Stock-based compensation expense rose to $8.1M from $5.6M.

05-03-2026

Invivyd reported product revenue of $53.4M for FY 2025, more than doubling YoY from $25.4M (+110.5%), driven by commercial progress, while R&D expenses plummeted 72% to $38.3M amid cost controls. However, SG&A expenses rose 6% to $66.9M, total operating expenses remained elevated at $109M, and the company posted a net loss of $52.5M (improved from $169.9M prior year). Cash and equivalents surged to $226.7M, bolstered by $215.6M in net financing proceeds, though operating cash burn persisted at $58.1M.

• ·Net cash used in operating activities improved to $(58.1M) from $(170.5M) YoY.
• ·Proceeds from public offering net: $182.5M; ATM offering net: $33.4M in FY2025.
• ·Loan and Security Agreement with Silicon Valley Bank dated April 18, 2025.
• ·Controlled Equity Offering Sales Agreement with Cantor Fitzgerald dated Dec 22, 2023.
• ·Clinical Master Services Agreement with WuXi Biologics dated July 21, 2020.
• ·Diluted EPS: $(0.30) FY2025 vs $(1.43) FY2024.

05-03-2026

Compass Therapeutics, Inc. (CMPX) filed its 10-K annual report on March 05, 2026, highlighting significant commercialization risks, including dependence on third-party payors for coverage and reimbursement, compliance with extensive U.S. federal, state, and foreign laws (e.g., anti-kickback, false claims, GDPR effective May 2018), and the need to establish marketing, sales, and distribution infrastructure. The company has never generated revenue from product sales and may never be profitable, while facing manufacturing risks such as delays, shortages, and potential recalls. Under equity compensation plans, 1.0 million shares of common stock are issuable upon vesting of restricted stock units.

• ·Equity compensation values exclude weighted average exercise price calculation per disclosure.
• ·Risks include post-approval requirements like REMS that could limit promotion, advertising, distribution, or sales.

05-03-2026

Kura Oncology reported total revenue of $67.5M for FY2025, up 25% YoY from $53.9M, driven by first-ever product revenue of $2.1M and 21% growth in collaboration revenue to $65.4M. However, net loss widened 60% YoY to $279M amid R&D expenses surging 48% to $251M and SG&A up 56% to $120M, leading to negative operating cash flow of $64M versus $134M inflow prior year, cash and equivalents dropping to $149M from $225M, and stockholders' equity halving to $174M.

• ·Long-term debt totals $10M, due in 1-3 years.
• ·Total contractual obligations $37M, with $23.967M in operating leases.
• ·Accumulated deficit grew to $1.174B from $895M.
• ·Short-term investments increased to $518M from $503M.

05-03-2026

Bioventus Inc. reported net sales of $568.1M for FY2025, a slight decline of 0.9% YoY from $573.3M, driven by sharp drops in Restorative Therapies (-29.5% U.S., -35.6% International) despite growth in Pain Treatments (+5.7% U.S., +17.0% International) and Surgical Solutions (+7.6% U.S., +7.7% International). Profitability improved markedly with net income of $27.3M versus a $47.0M loss in 2024, Adjusted EBITDA rising 6.8% to $116.3M, gross margin expanding to 68.3%, and operating income reaching 9.5% versus a 2.7% loss. U.S. and International sales both fell slightly by 0.9% and 0.7%, respectively.

• ·Depreciation and amortization declined 25.2% to $5.7M in FY2025.
• ·Income tax benefit narrowed to $1.6M from $5.3M, with effective tax rate at 6.1% versus 10.1%.
• ·Shareholder litigation costs dropped to $51K from $13.8M.
• ·Total contractual obligations amount to $451.6M.

05-03-2026

For the year ended December 31, 2025, Distribution Solutions Group reported consolidated revenue of $1.98B, up 9.8% YoY from $1.80B, with strong growth in Gexpro Services (+12.7% to $497M) and Canada Branch Division (+77.1% to $221M), while Lawson (+2.6% to $481M) and TestEquity (+1.6% to $783M) showed modest increases. Operating income improved to $78.3M (4.0% margin) from $56.0M (3.1%), and net income swung to a profit of $8.3M from a $7.3M loss; however, adjusted EBITDA was essentially flat at $175.2M (vs. $175.3M) and gross margin declined slightly to 33.4% from 34.0%.

• ·Lawson end markets: Automotive 31%, Manufacturing 14%; Product categories: Aftermarket automotive supplies 21%, Fastening systems 16%.
• ·TestEquity end markets: Electronics manufacturing 31%, Aerospace and defense 20%.
• ·Interest expense stable at ~$55M YoY.
• ·Depreciation and amortization increased to $80.9M from $74.4M.

05-03-2026

Silence Therapeutics plc reported FY2025 revenue of $0.6M, a 99% YoY decline from $43.3M, driving net loss to $88.6M from $45.3M and operating loss to $91.1M from $63.3M, exacerbated by restructuring charges of $1.3M and foreign currency losses. Cash and equivalents dropped sharply to $11.3M from $121.3M, with total assets falling to $131.4M from $202.6M. However, G&A expenses improved 17% YoY to $22.3M, R&D costs remained nearly flat, and operating cash outflow lessened 8% to $62.3M.

• ·Short-term investments increased to $73.8M from $26.0M as of Dec 31 2025.
• ·Restructuring charges of $1.3M recognized in FY2025.
• ·Net cash outflow from investing activities increased to $48.0M from $22.0M.
• ·Financing cash inflow minimal at $15k in FY2025 vs $142.1M in FY2024.
• ·Loss per share (basic and diluted) $0.63 in FY2025 vs $0.33 in FY2024.

05-03-2026

Aligos Therapeutics reported a sharply reduced net loss of $24.2M for the year ended December 31, 2025, compared to $131.2M in 2024 (-82% YoY), primarily due to a $60.2M gain from the change in fair value of 2023 Common Warrants and slight declines in operating expenses (total OpEx -3% to $90.2M). However, total revenue fell 45% YoY to $2.2M amid a complete drop in collaboration revenue (-100%) and customer revenue decline (-39% to $2.2M), while cash and equivalents decreased to $18.3M from $37.0M with operating cash burn of $82.5M. The company raised $101.6M net via PIPE financing, boosting total assets to $88.5M (+26%) and flipping stockholders' equity to a positive $53.5M from a $29.0M deficit.

• ·Net cash used in investing activities increased to $37.8M in 2025 from $18.3M in 2024, driven by short-term investment purchases.
• ·Stock-based compensation expense declined to $5.0M in 2025 from $8.5M in 2024.
• ·Net loss per share improved to ($2.45) in 2025 from ($20.94) in 2024.
• ·Restricted cash remained flat at $110K.

05-03-2026

flyExclusive, Inc. reported FY2025 revenue of $375.9M, up 14.9% YoY from $327.3M, with strong growth in fractional ownership (+66.1% to $37.7M) and maintenance, repair, and overhaul (+48.2% to $10.6M), while jet club and charter rose 10.2%. However, the company recorded a net loss of $67.1M (improved 33.9% from $101.5M), attributable net loss of $17.6M (down 16.5% from $21.1M), with total costs and expenses up 3.2% and average aircraft on certificate declining to 92 from 101. Adjusted EBITDA improved to -$7.0M from -$56.2M and Adjusted EBITDAR turned positive at $12.4M from -$36.4M, though cash and equivalents fell to $29.3M from $31.7M.

• ·Cash provided by operating activities: $6.7M in FY2025 vs used $10.9M in FY2024
• ·Net cash from investing activities: $108.9M in FY2025 vs used $7.9M in FY2024
• ·Total liabilities: $524.3M as of Dec 31 2025 (down from $550.0M)
• ·Redeemable noncontrolling interest: $213.4M as of Dec 31 2025 (up from $159.5M)
• ·Stockholders' deficit: $325.6M as of Dec 31 2025 (worsened from $210.1M)

05-03-2026

Acorn Energy, Inc. reported FY2025 revenues of $11.5M, up 4.5% YoY from $11.0M, driven by OmniMetrix with gross profit margin improving to 77% from 73%; operating income rose slightly 2.7% to $2.0M. However, net income attributable to stockholders fell sharply 60% to $2.5M from $6.3M due to a lower deferred tax benefit ($0.5M vs $4.4M), resulting in diluted EPS declining to $0.99 from $2.51; the Critical Power (CP) segment revenues dropped 33% to $0.7M (6% of total) from $1.1M (10%), and total hardware revenues decreased 8% to $5.9M.

• ·R&D expense increased 8% YoY to $1.1M from $1.0M.
• ·SG&A expense rose 13.5% YoY to $5.7M from $5.1M.
• ·Deferred income tax benefit $0.5M in FY2025 vs $4.4M in FY2024.
• ·Lease obligations: $41k (2026), $42k (2027), $33k (2028).
• ·Stock option grants: 2,200 options at $17.50 (2025) and $17.89 exercise prices.

05-03-2026

Okta, Inc. reported total revenue of $2.9B for the year ended January 31, 2026, up 12% YoY from $2.6B in 2025, primarily driven by 12% subscription revenue growth to $2.9B, while professional services revenue grew 18% to $64M. Gross profit increased 13% to $2.3B with gross margin expanding to 77%, leading to operating income of $149M and net income of $235M, a sharp turnaround from a $74M operating loss and $28M net income in 2025. However, R&D expenses declined slightly by 1% to $639M, sales and marketing rose 5% to $1.0B, and G&A remained flat at $448M.

• ·Subscription revenue represented 98% of total revenue in FY2026, unchanged from FY2025.
• ·Total cost of revenue increased 7% YoY to $661M in FY2026.
• ·Stock-based compensation expense decreased to $544M in FY2026 from $565M in FY2025.
• ·Restructuring and other charges fell to $4M in FY2026 from $11M in FY2025.

05-03-2026

CorMedix Inc. reported FY2025 total revenue of $311,709, up 617% YoY from $43,472, driven by DefenCath product sales of $258,813 (up from $43,472) and new Melinta Portfolio sales of $45,531, alongside contract revenue of $7,365. The company achieved a dramatic turnaround to net income of $163,055 from a $17,930 loss, with operating income of $150,141 versus a prior-year loss of $22,356 and gross profit of $275,748 (up 585%). However, total operating expenses increased 101% to $125,607, with G&A up 128% to $68,220 and selling/marketing up 32% to $38,054, while a $6,501 unfavorable change in contingent consideration partially offset other income.

• ·Agreement and Plan of Merger with Melinta Therapeutics, LLC dated August 7, 2025
• ·Accrued returns allowance of $18.3M as of December 31, 2025, including for Melinta Portfolio
• ·Company achieved cumulative pre-tax income over the most recent three-year period as of September 30, 2025, supporting realizability of certain deferred tax assets

05-03-2026

RAND Capital Corp's annual 10-K for the year ended December 31, 2025, reports sharp declines including total assets down 26.6% YoY to $53.2M from $72.5M, net assets down 20.1% to $52.2M, investments at fair value down 31.5% to $48.5M, and net unrealized depreciation of $8.6M versus $2.7M appreciation prior year. While liabilities decreased 85.8% to $1.0M and new investments added $6.6M, portfolio at cost fell 16.2% due to $19.8M in repayments, sales, and liquidations, reducing active portfolio companies from 22 to 20; realized losses totaled $2.0M compared to $11.1M gains in 2024.

• ·Annual expenses total 5.51% of net assets, including 1.53% base management fees and 0.36% incentive fees.
• ·Top holdings at Dec 31, 2025: EFINEA ($5.2M, 10%), Caitec ($5.1M, 9%), First Coast Mulch ($3.9M, 7%).
• ·Stock traded at discounts to NAV throughout most quarters in 2024 and 2025, with premiums up to 29.60% in Q1 2025.

05-03-2026

NATIONAL RESEARCH CORP reported FY2025 revenue of $137.4M, down 4% YoY from $143.1M, with operating income declining 36% to $22.6M due to a 22% rise in SG&A expenses to $54.8M and higher interest costs, resulting in net income of $11.6M versus $24.8M in 2024. However, Total Recurring Contract Value increased 8% to $144.1M, Adjusted EBITDA held steady at $40.2M (29.2% margin), and cash from operations was $26.5M. Shareholders' equity fell to $14.0M amid $20.7M in treasury stock repurchases and increased notes payable to $79.0M.

• ·Dividends declared $0.52 per common share in FY2025 ($11.8M total).
• ·Capital expenditures $10.7M in FY2025, down from $15.4M in FY2024.
• ·Purchase of 1,340,224 treasury shares for $20.7M in FY2025.
• ·Notes payable borrowings $47.7M and payments $31.4M in FY2025.
• ·Non-recurring executive compensation $6.6M added back for adjusted net income.
• ·Allowance for doubtful accounts $80K as of Dec 31 2025.

05-03-2026

Global Crossing Airlines Group Inc. reported total revenue growth of 10.1% YoY to $246.3M for the year ended December 31, 2025, driven by ACMI revenue surging 42.8% to $175.8M, while Charter revenue declined sharply 34.8% to $62.3M and total Charter block hours fell 39.6%. Operating income improved to a positive $8.9M from a $1.1M loss, with operating expenses up only 5.6% to $237.4M despite rises in salaries (18.8%) and maintenance (44.7%), but the company recorded a net loss of $2.6M (improved from $11.4M) amid higher interest expense (28.5%). Cash from operations rose significantly to $28.1M, supporting total assets of $203.1M up from $166.7M.

• ·Cash and cash equivalents increased to $16.7M from $12.3M as of Dec 31, 2025.
• ·Stockholders’ deficit remained relatively flat at approximately $29.5M.
• ·Total block hours grew 16.5% to 33,564.
• ·Aircraft rent expense nearly flat at $57.4M (-0.4%).
• ·Loss per share improved to $(0.05) from $(0.19).

05-03-2026

For the three months ended January 30, 2026 (Q1 FY2026), Toro Co reported net sales of $1,036.3M, up 4.1% YoY from $995.0M, with net earnings rising 28.6% to $67.9M driven by higher operating earnings ($87.1M, +12.0%) and other income. However, gross profit remained essentially flat at $336.5M (+0.3%), operating cash flow was modest at $26.1M after improving from a negative $48.6M YoY, and a $210.3M acquisition significantly increased investing outflows and goodwill to $592.1M.

• ·Professional segment external net sales $809.4M; Residential $206.0M; Other $20.9M.
• ·Goodwill increased to $592.1M from $449.8M YoY due to acquisition.
• ·Stockholders’ equity declined to $1,419.2M from $1,467.6M YoY.
• ·Weighted-average basic shares outstanding decreased to 98.0M from 101.3M YoY.
• ·Other segment reported pre-tax loss of $49.7M.

05-03-2026

Carter Bankshares, Inc. reported net interest income growth of 14.3% YoY to $130.8M in 2025 from $114.5M in 2024, with net interest margin expanding to 2.82% from 2.57% and average earning assets rising to $4.64B. Loan portfolio averaged $3.76B, up from $3.56B, driven by commercial real estate and construction loans. However, noninterest expenses increased 6.4% to $117.1M, outpacing 4.8% growth in noninterest income to $22.4M, while insurance commissions declined 26.0% and total liquidity sources fell to $1.23B from $1.39B.

• ·Highly Liquid Assets to Uninsured Deposits declined to 59.8% in 2025 from 66.8% in 2024.
• ·Federal Home Loan Bank Borrowings decreased to $110.9M average in 2025 from $222.7M in 2024.
• ·Pretax Net Interest Income sensitivity: +200 bps change results in -1.0% impact in 2025.

05-03-2026

Uwharrie Capital Corp reported net income attributable to common shareholders of $10.8M for 2025, up 15.5% YoY from $9.3M, driven by net interest income growth of 8.1% to $38.9M and noninterest income up 15.7% to $11.3M; total assets expanded 6.0% to $1.20B with loans held for investment up 3.5% to $690M. However, certain noninterest income streams declined, including interchange fees down 8.3% to $1.1M and other banking fees down 9.8% to $0.9M, while noninterest expenses rose 7.4% to $34.8M. EPS basic increased 18.3% YoY to $1.49.

• ·Provision for credit losses increased to $726K in 2025 from $528K in 2024.
• ·Allowance for credit losses on loans: $6.4M (2025) vs $5.8M (2024).
• ·Accumulated other comprehensive loss improved to $(16.6M) from $(24.7M) YoY.

05-03-2026

ParkOhio Holdings Corp reported net sales of $1,599.1 million for 2025, down 3% YoY from $1,656.2 million, with declines across all segments: Supply Technologies -3%, Assembly Components -4.5%, and Engineered Products -2.2%. Operating income fell 23% to $66.3 million, driven by sharp drops in Engineered Products operating income to $6.6 million (1.4% margin from 3.7%) and asset impairment charges of $8.9 million; however, Supply Technologies held steady at 9.7% operating margin and gross margin remained flat at 17.0%. Income attributable to common shareholders declined 41% to $24.8 million ($1.77 diluted EPS), though operating cash flow improved to $42.3 million.

• ·Cash provided by operating activities increased to $42.3M in 2025 from $35.0M in 2024.
• ·Gross debt rose slightly to $635.7M in 2025 from $628.7M in 2024, but net debt as % of capitalization improved to 58% from 60%.
• ·Restructuring and other special charges increased 31% YoY to $6.4M in 2025.
• ·Decrease in cash and cash equivalents was $8.3M in 2025 vs $1.7M in 2024.

05-03-2026

Solitario Resources Corp. reported a narrowed net loss of $3.8M for 2025 compared to $5.4M in 2024, driven by lower exploration expenses (-31% YoY to $2.8M) and G&A (-17% YoY to $1.6M), while total operating expenses declined 27% YoY to $4.4M. Total assets grew 9% YoY to $25.0M, supported by short-term investments surging 68% to $7.6M, however marketable equity securities dropped 78% to $0.3M and cash remained flat at $0.08M. Shareholders' equity increased 10% YoY to $24.7M amid share issuances, though operating cash use improved modestly to $3.6M from $5.1M.

• ·Shares issued via ATM net: 1,007k shares for $0.73M in 2025 vs 1,802k for $1.22M in 2024.
• ·Private placement: 7.1M shares for $4.4M in 2025.
• ·Net cash provided by financing: $5.3M in 2025 vs $1.3M in 2024.
• ·Investing cash used $1.8M in 2025 (driven by $3.1M net purchase of short-term investments) vs provided $3.9M in 2024.

05-03-2026

L.B. Foster's net sales rose 1.7% YoY to $540M in 2025 from $531M in 2024, bolstered by 14.9% growth in the Infrastructure segment to $234M, while the Rail segment declined 6.5% to $306M. Gross profit fell 3.6% to $114M with margin contracting 110 bps to 21.1%, and operating income edged up 6.7% to $22M; however, net income plummeted 83% to $7.5M from $43M due to a $38M swing to tax expense. Operating cash flow improved significantly to $36M from $23M.

• ·Diluted EPS declined to $0.69 from $3.89 YoY.
• ·Total assets decreased to $330M from $334M.
• ·Outstanding borrowings on revolving credit facility: $42M; letters of credit: $0.9M as of Dec 2025.
• ·Critical audit matter identified on revenue recognition for long-term contracts using input method.
• ·Shares outstanding decreased to 10.1M from 10.6M due to treasury stock purchases.

05-03-2026

Intrepid Potash, Inc. reported total sales of $298.3M for 2025, up 17.2% YoY from $254.7M, with gross margin surging 88.5% to $54.8M from $29.1M and net income turning positive at $11.2M versus a $212.8M loss in 2024. Potash sales volumes increased 20.4% to 289K tons while Trio® volumes rose 19.3% to 303K tons with higher prices ($367/ton vs $311); however, Potash average price declined 6.4% to $353/ton and cash flows from operations fell 23.1% to $55.8M from $72.5M.

• ·Total assets increased to $632.2M from $594.5M; stockholders' equity rose to $491.4M from $474.4M.
• ·Potash production volumes declined slightly to 280K tons from 295K tons.
• ·Trio® production volumes increased to 273K tons from 251K tons.

05-03-2026

Quest Water Global, Inc. (QWTR) reported a significantly larger net loss of $291,413 for the three months ended September 30, 2025, compared to $137,329 in the prior year (112% YoY increase), driven by new marketing expenses and higher management fees. For the nine months ended September 30, 2025, the net loss edged up 3.4% YoY to $630,907 from $610,054, while total expenses rose modestly to $630,907. Stockholders' deficit widened to $2.94M from $2.26M YoY amid continued cash burn from operations funded by related party advances.

• ·Management fees for nine months ended Sep 30, 2025: $401,250 (up from $371,250 YoY)
• ·Stock-based compensation: $99,200 in Q3 2025 (nine months total includes prior periods)
• ·Cash and equivalents end of nine months: $9 (down from $12 YoY)
• ·Computer equipment fully depreciated to $0 net book value as of Sep 30, 2025

05-03-2026

TriSalus Life Sciences reported strong revenue growth of 53.4% YoY to $45.2M for the year ended December 31, 2025, with gross profit up 50.8% to $38.2M and R&D expenses down 15.4% to $15.0M, improving operating loss by 25.5% to $(26.9M). However, sales and marketing expenses rose 11.1% to $28.7M, G&A increased 19.4% to $21.5M, and net loss widened 30.6% to $39.2M amid higher interest expense (up 79.4%) and unfavorable changes in fair value liabilities. Cash and equivalents grew to $20.4M from $8.5M, bolstered by $30.8M in financing activities, though net cash used in operations remained negative at $18.0M (improved from $40.8M).

• ·Common shares outstanding increased to 49,997,836 from 31,279,264 YoY due to sales, conversions, and exercises.
• ·Total liabilities rose to $69.2M from $49.9M, driven by long-term debt up to $33.0M and warrant/SEPA liabilities to $12.9M.
• ·Net cash provided by financing activities totaled $30.8M, including $22.0M from common stock issuance and $10.0M from debt.
• ·Stock-based compensation expense increased to $9.8M from $5.4M.
• ·Cash paid for interest rose to $3.7M from $1.8M.

05-03-2026

NCS Multistage Holdings, Inc. reported total revenues of $183.6M for the year ended December 31, 2025, up 13.0% YoY from $162.6M, driven by strong U.S. growth of 33.5% but tempered by modest 4.7% growth in Canada. Net income rose 219.9% to $26.0M, boosted by a $9.2M tax benefit, while operating income increased 143.7% to $10.5M; however, services gross margin declined to 45.0% from 48.7%, and other countries services revenues fell 31.1% YoY.

• ·Net cash provided by operating activities increased to $22.2M in 2025 from $12.7M in 2024.
• ·U.S. services revenues surged 87.8% YoY to $18.0M.
• ·Product sales revenues grew 13.1% YoY to $127.9M, with Other Countries up 126.1%.
• ·Provision for litigation of $0.9M in 2025.
• ·Filing date: March 05, 2026 for year ended December 31, 2025.

05-03-2026

Camp4 Therapeutics' revenue surged 436% YoY to $3.5M in 2025 from $0.65M, driven by research and collaboration agreements, while R&D expenses remained flat at approximately $38.2M-$38.8M. However, net loss widened 55% to $80.4M from $51.8M primarily due to a $29.8M unfavorable change in fair value of derivative tranche liability, despite improved operating cash use to $29.6M from $45.6M and a strengthened cash position of $109.5M. Stockholders' equity declined to $47.7M from $63.1M amid significant share issuance.

• ·Derivative tranche liability recorded at $44.8M as of Dec 31, 2025.
• ·Issuance of 31.7M common shares in private placement and registered direct offering in 2025, net proceeds $57.3M.
• ·Initial public offering in 2024 converted preferred stock and raised net $72.4M.
• ·Net loss per share improved to ($2.65) from ($11.04) due to increased shares outstanding.
• ·Impairment of right-of-use asset $0.5M in 2025.

05-03-2026

Cedar Realty Trust, Inc. reported a net loss of $1.9M for the year ended December 31, 2025, compared to a $4.5M profit in 2024, primarily due to a 14.1% decline in revenues to $29.7M, higher impairment charges of $5.8M (up 442.8%), and a reduction in properties owned from 16 to 12. However, Same-Property NOI grew slightly to $17.1M from $16.8M with flat occupancy at 92.4%, FFO increased to $19.3M (per share $1.41 from $0.52), and AFFO turned positive at $1.0M; the company also repurchased 4,244 shares of Series C Preferred Stock for $69K in October 2025.

• ·Same-Property occupancy flat at 92.4% (end of 2025 and 2024).
• ·Aggregate gross leasable area declined to 1,943,176 sq ft from 2,352,528 sq ft.
• ·Cash flows from operating activities down to $8.0M from $9.5M; financing activities outflow increased to $52.7M from $20.3M.
• ·Total liabilities slightly up to $158.8M from $160.7M despite property sales.
• ·Preferred stock equity down to $76.2M from $139.8M.

05-03-2026

Evommune, Inc. (EVMN) reported FY2025 revenue growth of 86% YoY to $13M from $7M, primarily from license revenue, while completing an IPO with $157M net proceeds and converting all convertible preferred stock, boosting total assets to $225M and cash equivalents to $44.1M. However, operating expenses increased 22% YoY to $94.1M driven by 15% higher R&D ($74M) and 57% higher G&A ($20M), resulting in a widened net loss of $68.9M (up 3% YoY) and increased operating cash use to $76.4M. EVO301 R&D expenses declined sharply to $7.1M from $19.7M, while EVO756 R&D rose to $35.2M.

• ·Convertible preferred stock fully converted to common stock upon IPO, eliminating $257M non-cash liability.
• ·Stockholders' equity swung from ($144.2M) deficit in 2024 to $205.6M surplus in 2025.
• ·Property and equipment, net declined to $0.99M from $1.33M.
• ·Weighted average shares outstanding increased to 6.14M from 1.51M, reducing basic/diluted loss per share to ($11.22) from ($45.29).

05-03-2026

Hawthorn Bancshares, Inc. (HWBK) filed its 10-K annual report on March 5, 2026, covering the fiscal year ended December 31, 2025, with comparative data for 2024 and 2023 across banking and fiduciary/trust segments. The filing discloses detailed loan portfolio segments including commercial financial/agricultural, real estate construction (residential and commercial), real estate mortgages (residential and commercial), and installment/consumer loans, along with securities holdings, property/equipment, derivatives, and subordinated notes. No specific numerical financial metrics such as revenue growth, declines, or balance sheet totals are provided in the extracted XBRL tags.

• ·Filing covers periods: FY2025 (Jan 1 - Dec 31, 2025), FY2024, FY2023, with some Q4 2025 data.
• ·Loan classifications include Pass, Watch, Special Mention, Substandard, Doubtful; nonperforming and past due receivables tracked by segment.
• ·Securities categories: US Treasury, US Government Agencies/Sponsored Enterprises, States/Political Subdivisions, Mortgage-Backed, Other Debt, Equity.
• ·Trusts issued: Exchange Statutory Trust Two (Mar 17, 2005), Exchange Statutory Trust One (Mar 17, 2004).
• ·Shelf registration referenced as of July 2, 2025; 2025 Repurchase Plan authorized June 5, 2025.

05-03-2026

A.K.A. Brands Holding Corp. reported net sales growth of 4.4% YoY to $600.2M for FY 2025, with gross margin stable at 57% and net cash from operating activities surging to $16.4M from $0.7M. However, net loss widened 21% YoY to $31.4M, Adjusted EBITDA declined 15% to $19.7M (3% margin from 4%), and free cash flow remained negative at $0.6M despite improvement from -$10.9M.

• ·Distribution center relocation costs: $4.6M in FY2025 (up from $2.1M in FY2024)
• ·Non-routine legal matters: $6.6M in FY2025 (up from $4.5M in FY2024)
• ·Goodwill impairment: $0 in FY2025 (vs $68.5M in FY2023)
• ·Purchases of property and equipment: $17.1M in FY2025 (up from $11.6M in FY2024)

05-03-2026

BCP Investment Corp (BCIC) reported total assets of $523.6M as of December 31, 2025, up 15.4% YoY from $453.6M, driven by portfolio fair value growth to $501.0M (+23.7% YoY) bolstered by the $153.4M LRFC Acquisition; net asset value rose 17.2% YoY to $209.2M. However, total investment income declined slightly 2.0% YoY to $61.2M, with core investment income dropping 12.7% YoY to $54.3M amid lower interest and CLO income, while net expenses decreased 6.2% YoY to $36.0M. Unrealized gains on investments improved to $6.5M from $1.0M in 2024.

• ·Non-controlled/non-affiliated investments fair value: $409.7M (Dec 31, 2025) vs $327.6M (Dec 31, 2024), +25.1% YoY
• ·Total liabilities increased to $314.5M (+14.3% YoY) from $275.1M, with new debt issuances including $72.6M 2030 Notes
• ·Realized losses on investments: $21.4M in 2025 vs $29.4M in 2024

05-03-2026

Keysight Technologies reported Q1 FY2026 revenue of $1.6B, up 23% YoY driven by 25% growth in products and 19% in services; however, operating income rose only 14% to $248M due to cost increases outpacing revenue in areas like cost of products (+30%) and SG&A (+24%), resulting in margin compression to 15.5% from 16.8%. Net income surged 66% to $281M primarily from an $83M tax benefit versus prior $30M expense, boosting diluted EPS to $1.63 from $0.97. Operating cash flow improved 17% to $441M, while the company repurchased $87M in shares.

• ·Tax provision was a benefit of $83M vs $30M expense YoY due to discrete items.
• ·Interest expense increased to $29M from $20M YoY.
• ·Acquired business for $1.564B total consideration on Oct 15, 2025, with $711M goodwill.
• ·Small acquisition of $16M in current quarter cash flows.
• ·Total assets $11.481B as of Jan 31, 2026, up from $11.301B at Oct 31, 2025.

05-03-2026

EyePoint Pharmaceuticals reported total revenues of $31.4M for FY 2025, down 28% YoY from $43.3M, with product sales declining 50% to $1.6M and license/collaboration revenues dropping 57% to $16.7M, though royalty income surged 708% to $13.0M. Operating expenses rose 45% to $274.8M, primarily due to a 66% increase in R&D to $221.0M, resulting in a net loss of $232.0M, up 77% from $130.9M in FY 2024. Cash and equivalents stood at $101.8M as of Dec 31, 2025, with net cash used in operations worsening to $240.1M and stockholders' equity declining to $306.1M.

• ·Marketable securities decreased to $204.3M from $271.2M as of Dec 31, 2025.
• ·Total current assets down to $328.7M from $383.3M.
• ·Stock-based compensation expense $27.9M in FY 2025 vs $36.7M in FY 2024.
• ·Issuance of common stock net of costs: 13.7M shares raising $172.9M in FY 2025.

05-03-2026

Amalgamated Financial Corp. (AMAL) reported total assets of $8.5B as of December 31, 2025, up from $8.3B in 2024, with net interest income growing 5.4% YoY to $297.8M on higher loan volumes (+$25.2M interest income) and total interest income up 5.2% to $422.2M at a 5.09% yield. However, non-interest income declined 6.9% YoY to $30.9M amid losses on securities sales and equity investments, while non-interest expenses rose 7.9% to $172.2M driven by higher compensation, professional fees, and technology costs; nonperforming assets also edged up slightly to $28.7M or 0.32% of assets.

• ·Average total loans grew to $4,720M in 2025 from $4,479M in 2024 (+5.4% YoY).
• ·Nonaccrual loans in commercial portfolio rose to $22.1M from $16.0M YoY.
• ·Allowance for credit losses on loans to total loans declined to 1.16% from 1.29% YoY.
• ·Service charges on deposit accounts dropped sharply to $17.5M from $32.2M YoY.

05-03-2026

Mobile Infrastructure Corp reported total revenues of $35.1M for the year ended December 31, 2025, down 5.2% YoY from $37.0M, with managed property revenue up modestly 2.8% to $28.6M but offset by sharp declines in base rental income (-12.9% to $5.4M) and percentage rental income (-64.2% to $1.1M). Net Operating Income fell 8.5% to $20.7M amid a surge in impairment charges to $3.8M (from $0.2M) and higher interest expense (up 37.7% to $19.0M), resulting in a net loss of $23.7M versus $8.4M in 2024. The company outlined objectives to optimize RevPAS and pursue acquisitions but highlighted ongoing risks from parking demand fluctuations and high debt levels.

• ·Total other expense increased 107.8% YoY to $20.6M in 2025.
• ·Loss on sale of real estate was $0.1M in 2025 versus gain of $2.7M in 2024.

05-03-2026

Olaplex Holdings, Inc. reported flat net sales of $423M for FY 2025, up just 0.1% YoY from $423M in 2024, with Professional channel growing 5.5% to $153M but offset by an 8.3% decline in Specialty retail to $130M and modest 3.1% DTC growth. The company swung to a net loss of $9.3M from a $19.5M profit in 2024, driven by a 33.8% surge in SG&A expenses to $243M that caused operating income to plummet 90% to $7M, despite a slight 0.5% gross profit increase to $294M. Cash from operations fell sharply to $59M from $143M, leading to a $267M net decrease in cash.

• ·Cost of sales declined 0.8% YoY to $129M in FY 2025.
• ·Interest expense, net decreased 22.5% to $27M.
• ·Net cash used in financing activities was $313M in FY 2025 vs $19M in 2024.
• ·FY 2023 net sales were $458M, with net income of $62M.

05-03-2026

CIENA Corp reported Q1 FY2026 total revenue of $1.43B, up 33% YoY from $1.07B, with products surging 38% to $1.18B and services growing 14% to $247M; net income more than tripled to $150M from $45M, driving diluted EPS to $1.03 from $0.31. Gross profit rose 33% to $626M, while operating income jumped 135% to $189M. However, gross margin slipped slightly to 43.8% from 44.0% YoY, and operating expenses increased 11.5% to $436M amid higher R&D (+15%) and selling/marketing (+9%).

• ·Optical Networking revenue $1.02B, representing ~72% of total revenue in Q1 FY2026.
• ·Cash used in investing activities $44M vs $67M YoY.
• ·Net cash used in financing activities $155M, driven by $81M share repurchases and $90M tax withholdings.
• ·Accounts receivable, net stable QoQ at ~$967M-$976M, with allowance for credit losses flat at $11.2M.

05-03-2026

Research Frontiers Inc (REFR) reported a widened net loss of $2.05M in 2025 versus $1.31M in 2024, driven by a 16% YoY decline in fee income to $1.12M while operating expenses rose 20% to $2.64M and research and development expenses increased 7% to $0.61M. Cash and cash equivalents fell sharply 67% to $0.66M from $1.99M, with total assets dropping 44% to $2.25M and shareholders' equity declining 64% to $0.93M from $2.60M. Net cash used in operating activities more than doubled to $1.33M from $0.79M.

• ·Royalties receivable reserves increased to $1.38M in 2025 from $1.25M in 2024.
• ·Credit loss expense rose to $154k in 2025 from $25k in 2024.
• ·Directors fees and expenses increased to $338k in 2025 from $176k in 2024.

05-03-2026

Phio Pharmaceuticals reported increased operating expenses of $9.22M for 2025 (up 24.8% YoY from $7.39M), driven by R&D (+26.8% to $4.62M) and G&A (+22.9% to $4.60M), resulting in a wider net loss of $8.70M (up 21.7% YoY from $7.15M). However, strong financing activities provided $23.64M in net cash, boosting cash and equivalents to $21.03M (up 290.9% from $5.38M) and total assets to $21.49M. Common shares outstanding surged to 11.62M from 1.73M due to issuances and warrant exercises.

• ·Net cash used in operating activities increased to $7.98M in 2025 from $7.11M in 2024.
• ·Interest income, net was $0.52M in 2025 vs $0.23M in 2024.
• ·Diluted net loss per share improved to $(1.45) in 2025 from $(9.08) in 2024 due to increased share count.
• ·Stock-based compensation expense was $0.48M in 2025 vs $0.15M in 2024.
• ·Offering costs for common stock and warrants issuance in 2025 totaled $2.9M.

05-03-2026

Orion Properties Inc. (ONL) reported total revenues of $147.6M for the year ended December 31, 2025, down 10.4% YoY from $164.9M, primarily due to a 10.5% decline in rental income and a reduced portfolio of operating properties (58 vs. 69). While occupancy improved to 78.7% from 73.7% and leased rate rose to 80.7% from 74.7%, net loss attributable to common stockholders widened to $(139.3M) or $(2.48) per share from $(103.0M) or $(1.84) per share, with FFO dropping 48.3% to $24.3M and Core FFO declining 23.1% to $43.7M amid surging impairments of $99.4M (up 109.1%).

• ·Investment-grade tenants declined to 66.7% from 74.4% as of Dec 31, 2025.
• ·Total capital expenditures rose to $60.0M in 2025 from $24.1M in 2024.
• ·Rentable square feet leased in 2025 totaled 924k vs 1,086k in 2024.
• ·Weighted average remaining lease term increased to 5.7 years from 5.2 years.

05-03-2026

Grove Collaborative Holdings, Inc. reported net revenue of $173.7M for the year ended December 31, 2025, down 15% YoY from $203.4M, driven by declines in both Grove Brands (-13%) and third-party products (-16%), alongside DTC total orders falling 17% to 2.42M and active customers dropping 13% to 599K. While gross margin remained flat at 54%, net loss narrowed to $11.7M from $27.4M, operating loss improved to $11.3M from $22.5M due to lower operating expenses, and Adjusted EBITDA was -$2.2M versus $1.3M prior year. Interest expense plunged 90% to $1.2M, but cash used in operations increased slightly in intensity despite a 29% reduction to $7.0M.

• ·DTC Net Revenue Per Order remained flat at $67.
• ·Cost of goods sold declined 14% YoY to $80.4M.
• ·Advertising expenses decreased to $9.7M from $10.3M; Product development fell sharply to $7.5M from $18.5M; SG&A down to $87.4M from $103.2M.
• ·Net cash used in investing activities increased to $4.0M from $1.6M.

05-03-2026

ArriVent BioPharma reported a significantly widened net loss of $166.3M for the year ended December 31, 2025, up 107% from $80.5M in 2024, primarily due to R&D expenses nearly doubling to $153.4M (+94%) and G&A rising 58% to $24.2M. While total assets increased 21% to $333.2M bolstered by $203.1M in financing inflows and short-term investments growing to $267.3M, cash and equivalents declined 39% to $45.5M amid heightened operating cash burn of $160.6M. Interest income also decreased 19% to $11.2M.

• ·Accumulated deficit increased to $404.6M as of Dec 31 2025 from $238.3M as of Dec 31 2024.
• ·Short-term investments rose to $267.3M as of Dec 31 2025 from $144.6M as of Dec 31 2024.
• ·Financing activities provided $203.1M in 2025 vs $186.6M in 2024.
• ·Investing activities used $71.2M in cash in 2025 vs $192.5M in 2024.

05-03-2026

Ambiq Micro, Inc. reported net sales of $72.5M for the year ended December 31, 2025, down 4.7% from $76.1M in 2024, reflecting a decline in top-line growth. However, gross profit increased 32.1% to $32.1M with margin expansion to 44.3% from 31.9%, driven by lower cost of sales, while net loss narrowed to $36.5M from $39.7M. Operating expenses rose, with SG&A up to $33.2M from $27.7M, but financing activities provided $106.4M in cash inflows.

• ·Non-GAAP net loss improved to $20.9M in 2025 from $28.6M in 2024.
• ·Net cash used in investing activities increased to $7.4M in 2025 from $3.7M in 2024.
• ·Filing date: March 05, 2026.

05-03-2026

Entravision Communications Corp reported consolidated net revenue of $447.6M for the year ended December 31, 2025, up 23% YoY from $365.0M, driven by explosive 90% growth in Advertising Technology & Services to $270.9M; however, Media revenue declined 20% to $176.7M and direct operating expenses for that segment were nearly flat at $109.6M. Operating loss widened 60% to $83.4M from $52.0M, impacted by a $55.4M impairment charge, $25.2M loss on lease abandonment, and $2.8M restructuring costs, resulting in a net loss of $79.2M that improved from $148.9M in 2024 but remained negative with EPS of $(0.87). Cash and equivalents fell to $59.4M from $95.9M, total assets decreased to $387.5M, and stockholders' equity dropped to $55.4M from $146.0M.

• ·Cash flow from operating activities $10.6M in 2025, down from $74.7M in 2024.
• ·Capital expenditures $6.8M in 2025 vs $7.5M in 2024.
• ·Dividends declared $0.20 per common share in 2025, unchanged from prior years.
• ·Basic and diluted EPS $(0.87) in 2025 vs $(1.66) in 2024.
• ·Net cash used in financing activities $41.0M in 2025.

05-03-2026

Allient Inc reported revenue of $554.5M for 2025, up 5% YoY from $530.0M, driven by strong Industrial demand in power quality solutions for data centers but partially offset by declines in the Vehicle segment due to lower power sports and truck demand. Gross profit rose 10% to $181.7M with margin expansion to 32.8%, operating income surged 46% to $44.0M, and net income increased 67% to $22.0M or $1.32 per diluted share; however, restructuring costs more than doubled to $4.0M, other expenses rose sharply, and backlog grew only 1% to $232.9M. Net debt improved to $139.7M from $188.1M, supported by operational cash flows.

• ·U.S. sales were 55% of total revenue in both 2025 and 2024.
• ·Quarterly dividend of $0.03 per share paid each quarter of 2025 and 2024, totaling $0.12 per share annually; payout ratio 9% in 2025 vs 15% in 2024.
• ·Bookings increased 15% YoY to $550.9M.
• ·Foreign currency impact favorable by $6.5M on 2025 revenue; revenue excluding FX $548.0M.
• ·Effective tax rate 23.3% in 2025 vs 21.9% in 2024.

05-03-2026

Weave Communications, Inc. reported revenue growth of 17% YoY to $239M for the year ended December 31, 2025, from $204M in 2024, primarily driven by subscription and payment processing revenue which rose 17% to $229M. However, net loss was nearly flat at $28.1M versus $28.3M prior year, operating expenses increased 14% to $203M, and onboarding revenue declined 2% to $3.5M while gross margins remained deeply negative in onboarding (-153%) and phone hardware (-9%) segments. Total gross margin improved slightly to 72% from 71%.

• ·Stock-based compensation expense remained flat at $32.1M in 2025 vs. $32.2M in 2024.
• ·Incurrence of $1.7M in acquisition transaction costs and $0.9M in amortization of acquisition-related intangibles in 2025 (none in 2024).

05-03-2026

Smith & Wesson Brands, Inc. (SWBI) reported strong Q3 FY26 results with net sales up 17% YoY to $136M and net income surging 79% YoY to $3.8M (EPS $0.08). However, nine-month FY26 net sales grew modestly 3.5% YoY to $345M, while net income declined sharply 53% YoY to $2.3M amid higher operating expenses and lower operating income (-27% YoY). Total assets contracted 4% to $538M as of January 31, 2026 from $560M at April 30, 2025, with inventories down 8% to $175M but cash falling to $18M.

• ·Operating cash flow for 9M FY26 improved to $40M from -$48M YoY.
• ·Company retired 31.7M treasury shares during the period.
• ·Dividends paid at $0.13 per share for Q3 and $0.39 for 9M FY26.
• ·Capex for 9M FY26 was $19M, up from $14M YoY.

05-03-2026

Total revenues grew 53% YoY to $14.6M in 2025 from $9.5M in 2024, driven by collaboration revenues surging 67% to $13.6M, though royalties, license and other revenues declined 30% to $0.9M. Operating expenses increased 65% to $51.2M, including a $14.8M impairment of intangible assets and R&D up 42% to $17.7M, while G&A was nearly flat up 2%; this contributed to a net loss attributable to Lineage of $63.5M or $(0.28) per share, widening sharply from $18.6M or $(0.09) due to a $35.7M unfavorable change in warrant liability. Cash and equivalents decreased to $40.8M from $45.8M, with shareholders' equity dropping to $43.3M from $77.0M.

• ·Cash used in operating activities improved to $(18.9M) from $(23.1M) YoY.
• ·Financing activities provided $27.0M in 2025 vs $35.9M in 2024.
• ·Warrant liabilities increased to $43.9M as of Dec 31, 2025 from $6.2M.
• ·Intangible assets, net decreased to $31.7M from $46.5M.
• ·Income tax benefit of $5.3M in 2025.

05-03-2026

Metagenomi, Inc. reported collaboration revenue declining 52% YoY to $25.2M in FY2025 from $52.3M in FY2024, primarily due to drops from Ionis (-19% to $24.6M), elimination of Moderna revenue, and Affini-T (-82% to $0.6M), resulting in a widened net loss of $87.9M versus $78.1M prior year. However, total operating expenses decreased 14% to $121.2M driven by lower R&D (-14% to $94.4M) and G&A (-16% to $26.8M), while net cash used in operations improved to $88.9M outflow from $109.1M, leading to a $14.3M net cash increase. Stockholders' equity stood at $158.6M, down from $234.9M, with total assets at $221.1M.

• ·Moderna collaboration revenue dropped to $0 from $18.7M in FY2024.
• ·Affini-T collaboration revenue declined to $0.6M from $3.1M.
• ·Cash and cash equivalents increased to $41.7M from $27.4M, but available-for-sale marketable securities fell to $119.1M from $220.9M.
• ·Stock-based compensation expense decreased to $11.9M from $16.2M.
• ·Net cash provided by investing activities was $103.5M in FY2025 versus ($88.2M) use in FY2024.

05-03-2026

aTyr Pharma reported total revenues of $0.19M for 2025, down 19% YoY from $0.235M amid declining license and collaboration income. Net loss widened to $74.1M from $64.0M in 2024, driven by 11% higher R&D expenses ($60.2M, led by Efzofitimod at $47.6M up 9%) and 28% increased G&A ($17.6M); however, cash used in operations improved to $62.0M from $69.1M, supported by $66.4M raised via at-the-market offerings. Total assets stood at $93.0M, down 4% from $96.8M, with stockholders' equity at $67.3M.

• ·Shares used in net loss per share: 92,985,359 in 2025 (up from 74,261,265 in 2024).
• ·Net loss per share improved to $(0.80) from $(0.86) YoY.
• ·Financing activities provided $66.0M in 2025 vs $39.9M in 2024, primarily from ATM offerings.
• ·Available-for-sale investments increased to $67.9M from $61.1M.

05-03-2026

WEBTOON Entertainment Inc. reported FY2025 revenue of $1.38B, up 2.5% YoY from $1.35B, with IP Adaptations surging 31.8% to $131.0M, while Paid Content grew just 0.4% to $1.09B and Advertising declined 1.1% to $164.3M. Operating loss improved 36.9% to $63.5M, but a $336.5M impairment on goodwill and intangibles (up 382.5% YoY) drove net loss to widen 144.2% to $373.4M from $152.9M. Adjusted EBITDA fell to $19.4M (1.4% margin) from $68.0M (5.0% margin).

• ·Cost of revenue increased 5.1% YoY to $1.06B.
• ·Marketing expenses rose 17.0% YoY to $126.1M.
• ·General and administrative expenses declined 21.8% YoY to $259.5M.
• ·Income tax benefit of $16.0M in FY2025 vs expense of $3.6M in FY2024.

05-03-2026

Rumble Inc. reported FY 2025 revenues of $100.6M, up 5% YoY from $95.5M in 2024, driven by modest growth, while cost of services declined 22% to $107.4M, improving the operating loss to $126.7M from $130.9M and significantly reducing net loss to $81.8M from $338.4M. However, total expenses rose slightly to $227.3M due to higher G&A (+33% to $48.7M), sales & marketing (+38% to $23.9M), and new $13.3M acquisition-related costs, with ongoing risks from advertising dependency and fixed creator incentives. The company continues to post net losses amid user engagement and advertiser retention challenges.

• ·Change in fair value of warrant liability contributed +$24.8M gain in 2025 vs -$32.7M loss in 2024
• ·Change in fair value of derivative contributed +$9.7M gain in 2025 vs -$185.0M loss in 2024
• ·Interest income increased to $10.4M from $8.1M

05-03-2026

Nutex Health, Inc. reported total revenue of $875M for the year ended December 31, 2025, up 82% YoY from $480M in 2024, primarily driven by Hospital division revenue surging 88% to $844M. However, Population health management division revenue remained essentially flat at $31M (up 0.7% YoY), Real estate division posted minor losses, and Q4 2025 revenue declined sharply 41% QoQ/YOY equivalent to $152M from $258M in Q4 2024. Net income attributable to Nutex Health rose 36% YoY to $71M, while Adjusted EBITDA increased 152% to $260M, though Q4 Adjusted EBITDA fell to $17M from $87M.

• ·Stock-based compensation expense rose sharply to $117M in 2025 from $17M in 2024.
• ·Cash and cash equivalents increased to $186M as of Dec 31, 2025 from $41M at end of 2024.
• ·Total assets grew to $919M from $655M year-over-year.
• ·Q3 2025 net income attributable to Nutex was a loss of $18M, compared to smaller loss of $9M in Q3 2024.
• ·Accrued arbitration expenses stood at $50M as of Dec 31, 2025.

05-03-2026

ESS Tech, Inc. reported FY2025 revenue of $1.6M, plummeting 75% YoY from $6.3M amid negative revenue adjustments of $0.8M partially offset by $2.4M from related parties. While gross loss narrowed 39% to $27.7M, operating expenses declined 33% to $29.7M, and net loss improved 26% to $63.4M versus $86.2M prior year, total assets shrank 29% to $51.2M and stockholders' equity dropped 70% to $8.6M from $28.9M.

• ·Cash and cash equivalents decreased slightly to $14.5M from $13.3M at Dec 31, 2025 vs 2024.
• ·Common shares outstanding doubled to 22.4M from 12.0M, driven by issuances under SEPA, ATM, and stock-based compensation.
• ·Deferred revenue - related parties dropped to $5.3M from $14.4M.

05-03-2026

RYAM's 2025 net sales declined 10% YoY to $1,466M from $1,630M, with gross margin dropping 28% to $119M (8.1% of sales) from $166M (10.2%), driven by lower volumes across most segments despite price gains in Cellulose Specialties. Operating income fell 90% to $4M from $39M, culminating in a net loss of $420M versus $39M loss in 2024, primarily due to a $323M tax expense. While Cellulose Specialties operating income remained resilient at $160M, other segments like Cellulose Commodities and Paperboard posted operating losses and sales declines.

• ·2024 Notes ($550M) and 2026 Notes ($500M) fully redeemed.
• ·2027 Term Loan ($250M) fully redeemed November 2024.
• ·Income from discontinued operations $3M in 2025.
• ·Asset impairment $0 in 2025 vs $25M in 2024.

05-03-2026

Caribou Biosciences reported licensing and collaboration revenue of $11.2M for 2025, up 12% YoY from $10.0M, driven by $2.8M growth from other licensees while Pfizer revenue remained flat at $2.5M. Research and development expenses declined 16% to $109.4M and general/administrative fell 18% to $37.9M, narrowing the net loss to $148.1M from $149.1M and improving cash used in operations by $27.2M to $111.0M. However, new impairment charges of $12.2M (plus $9.2M equity investment impairment) contributed to total assets shrinking 44% to $175.4M from $313.3M, with stockholders' equity dropping to $122.2M from $253.0M.

• ·Cash and cash equivalents declined to $12.4M from $16.3M as of Dec 31 2025.
• ·Marketable securities (short-term) decreased to $127.0M from $193.2M.
• ·Accumulated deficit increased to $596.5M from $448.4M.
• ·Weighted-average shares outstanding: 93.4M in 2025 vs 90.3M in 2024.
• ·Net loss per share: ($1.59) in 2025 vs ($1.65) in 2024.

05-03-2026

Wheeler Real Estate Investment Trust, Inc. (WHLRL) reported 2025 revenues of $99.4M, down 4.9% YoY from $104.6M, with net operating income declining 4.2% to $66.4M and operating cash flow dropping 18.7% to $21.1M amid a reduction in owned retail centers from 72 to 62. However, net income surged to $14.8M from $0.7M, driven by $14.4M gain on property disposals (up 158.6% YoY), while total debt decreased slightly to $482.8M and FFO available to common stockholders rose to $13.7M. Same-Property NOI grew modestly 1.6% to $60.2M, but impairment charges more than doubled to $2.9M.

• ·Series D Preferred Stock shares decreased to 107,522 in 2025 from 187,410 in 2024.
• ·Impairment charges increased 141.0% YoY to $2.9M.
• ·Interest expense rose 3.5% YoY to $33.8M.
• ·Weighted average rate increase on renewals improved to 11.7% from 9.5%.
• ·New leases sq ft increased to 252,374 from 230,953, with weighted avg change over prior rates at 26.4%.
• ·AFFO increased to $10.3M from $7.2M.

05-03-2026

Contineum Therapeutics, Inc. (CTNM) reported a widened net loss of $60M for the year ended December 31, 2025, up 42% YoY from $42M in 2024, driven by a 34% increase in total operating expenses to $68M, with R&D expenses rising 34% to $52M and G&A up 33% to $17M. However, the company significantly bolstered its liquidity, ending with $76M in cash equivalents (up from $22M) and $187M in marketable securities, supported by $113M in net financing proceeds from follow-on and at-the-market offerings, leading to total assets of $277M (up 30% YoY). While interest income remained relatively flat at $8M, cash used in operations nearly doubled to $55M YoY.

• ·Net loss per share improved slightly to $(2.17) from $(2.18) YoY.
• ·Class A common shares outstanding increased to 31.2M from 19.1M; Class B decreased to 6.1M from 6.7M.
• ·Accumulated deficit grew to $(177M) from $(117M).
• ·Follow-on offering net proceeds: $93M; ATM offering: $19M.
• ·No revenue reported (pre-revenue biotech).

05-03-2026

Gevo, Inc. reported total revenues of $160.6M for the year ended December 31, 2025, surging 849% YoY from $16.9M, primarily driven by new GevoND segment revenues of $136.8M (from $0) and GevoRNG up 14% to $18M. However, the company incurred a net loss attributable to Gevo of $33.8M, improved 57% from $78.6M but still reflecting elevated operating expenses ($180.8M, +68%), interest expense ($17.6M, +353%), and heavy investing cash outflows of $226.6M. Operating cash use narrowed to $13.4M from $57.4M, supported by financing inflows of $97.9M.

• ·Ethanol unit price averaged $1.70 per gallon in 2025.
• ·Corn cost per bushel $4.05; natural gas cost per MMBTU $2.89 in 2025.
• ·Average realized RIN price $1.93 (down 26% YoY); LCFS price $56.21 (up 11% YoY).
• ·RNG operating expenses declined 40% to $14.7M.

05-03-2026

NextCure, Inc. (NXTC) filed its 10-K annual report on March 05, 2026, highlighting significant risks including a limited operating history, no approved products, history of substantial losses, no revenue from product sales to date, and expectations of continued losses without profitability. The filing emphasizes challenges in establishing marketing, sales, and distribution capabilities for future product candidates and increasing compliance costs from privacy laws like CCPA and CPRA. Additional risks include state anti-kickback laws, false claims regulations, and the need for additional capital to fund operations.

• ·CPRA passed in November 2020 and effective January 1, 2023
• ·CCPA provides civil penalties and private right of action for data breaches

05-03-2026

ContextLogic Holdings Inc. (LOGC) reported zero revenue for the year ended December 31, 2025, a 100% decline from $43M in 2024, across all segments including core marketplace, ProductBoost, marketplace, and logistics. While operating expenses dropped 64% to $31M from $86M, narrowing the net loss attributable to common stockholders to $29M from $75M, cash used in operating activities improved to $16M from $94M but investing activities used $52M. Stock-based compensation remained relatively flat at $11M versus $12M.

• ·Sales and marketing expenses declined 100% to $0M from $18M YoY.
• ·Product development expenses declined 100% to $0M from $26M YoY.
• ·General and administrative expenses declined to $31M from $42M YoY.
• ·Provision for income taxes declined 100% to $0M from $6M YoY.
• ·Gross profit was $0M in 2025 versus $7M in 2024.

05-03-2026

REGENXBIO Inc. reported total revenues of $170.4M for the year ended December 31, 2025, a 105% YoY increase from $83.3M, primarily driven by license and royalty revenue surging 91% to $156.3M. However, research and development expenses rose 9.5% to $228.3M, total operating expenses increased to $331.6M, and the net loss narrowed to $193.9M from $227.1M but remained substantial; cash and cash equivalents declined to $34.5M from $57.5M, while stockholders' equity dropped sharply 60% to $102.7M amid rising royalty monetization liabilities.

• ·Direct expenses for ABBV-RGX-314 increased 3% YoY to $37.6M; RGX-202 up 83% to $26.3M; RGX-121 up 5.5% to $12.8M; other product candidates down 5% to $6.8M.
• ·Net cash used in operating activities improved to $124.0M from $173.1M.
• ·Proceeds from royalty bond and warrants: $144.5M in 2025.
• ·Interest expense rose to $45.0M from $12.7M.
• ·Property and equipment, net declined to $104.9M from $117.6M.

05-03-2026

Net interest income rose $4.7M YoY to $51.2M for 2025, with net interest margin expanding to 3.12% from 2.73%, driven by favorable rates despite lower volumes. However, average loans declined to $1.35B from $1.43B, total interest income fell $2.0M to $87.6M, and nonperforming assets increased to $16.7M from $14.3M. Non-interest income grew 10.25% to $11.1M supported by gains on loan sales (+32%), while non-interest expenses edged up 1.49% to $42.9M.

• ·Capital ratios remain strong: Total capital 14.6% (2025) vs 15.6% (2024), all well above well-capitalized thresholds.
• ·CRE portfolio: $443M Non-Owner Occupied, $240M Owner-Occupied, with criticized loans at 1.4%-7.9% of segments.
• ·Net loan recoveries of $58k in 2025 vs net charge-offs of $100k in 2024; NCOs (annualized) 0.00% vs (0.01)%.

05-03-2026

Ranger Energy Services, Inc. (RNGR) reported FY 2025 total revenue of $546.9M, down 4% YoY from $571.1M, primarily due to a sharp 37% decline in Wireline Services to $68.9M, while High Specification Rigs grew 3% to $347.0M and Processing Solutions increased 5% to $131.0M. Net income fell 33% to $12.3M from $18.4M, with operating income dropping 46% to $15.4M amid higher costs; Adjusted EBITDA was $73.2M, down from $78.9M. Cash from operating activities decreased 18% to $69.0M, though total assets expanded to $419.3M from $381.6M.

• ·Basic EPS declined to $0.55 from $0.81 YoY.
• ·Net cash used in investing activities increased to $76.1M from $31.1M.
• ·Borrowings under Revolving Credit Facility at $3.5M as of Dec 31, 2025.
• ·Property and equipment, net increased to $280.9M from $224.3M.

05-03-2026

Farmers National Banc Corp reported total assets of $5.16B at year-end 2025, up 1.5% from $5.09B in 2024, with average loans increasing 2% YoY to $3.29B at 5.82% yield and net interest income rising 11% to $145M with margin expanding to 2.95% from 2.69%. However, nonperforming assets rose 15% to $26.3M (0.50% of assets from 0.45%), nonperforming loans increased to $26.2M (0.79% of loans from 0.70%), and stockholders' equity grew to $441M amid merger integration risks with Middlefield. Quarterly cash dividends remained flat at $0.17 per share.

• ·Commercial real estate nonaccrual loans increased to $15.8M at Dec 31, 2025 from $10.6M in 2024.
• ·Loans delinquent 30-89 days rose to $17.0M (0.51% of loans) in 2025 from $13.0M (0.40%) in 2024.
• ·Allowance for credit losses covered 142% of nonaccrual loans at Dec 31, 2025, down from 162% in 2024.
• ·Total interest-bearing deposits averaged $3.41B in 2025, up from $3.26B in 2024.

05-03-2026

Clarus Corp's 10-K for year ended December 31, 2025, shows total sales declining 5.3% YoY to $250.4M from $264.3M, driven by a 9.0% drop in international sales to $144.3M despite a slight 0.4% rise in domestic sales to $106.1M. Gross profit fell 10.4% to $83.0M, but operating expenses decreased 12.5% to $142.7M, narrowing the operating loss to $59.7M from $70.4M and net loss to $46.6M from $52.3M amid lower restructuring charges and goodwill impairment, though indefinite-lived intangible impairment rose to $27.6M.

• ·Weighted average exercise price of outstanding options, warrants, and rights (excluding RSAs): $9.01.
• ·Annual goodwill impairment assessment as of December 31.
• ·Corporate headquarters owned in Salt Lake City, Utah; multiple Black Diamond and Rhino-Rack facilities leased.

05-03-2026

Profound Medical Corp. reported revenue growth of 51% YoY to $16.1M for the year ended December 31, 2025, with gross profit up 62% to $11.4M and gross margin expanding to 71% from 66%. However, net loss widened 53% to $42.6M driven by a 31% increase in operating expenses to $52.6M, including 39% higher SG&A and 21% higher R&D. Cash and cash equivalents rose to $59.7M from $54.9M, supported by $41.1M in financing activities despite $38.2M used in operations.

• ·Weighted average shares outstanding increased to 30.2M from 24.8M, contributing to loss per share rising 26% YoY to $1.41.
• ·Cash used in operating activities increased to $38.2M from $23.5M.
• ·Total contractual obligations $10.5M, with $5.9M due within one year.
• ·Accumulated deficit grew to $287.7M from $245.2M.

05-03-2026

South Plains Financial, Inc. reported net income of $58.5M for the year ended December 31, 2025, up 17.6% YoY from $49.7M in 2024, supported by net interest income growth of 13.6% to $167.0M and total assets expansion of 5.9% to $4.48B. However, noninterest income declined 6.6% to $44.9M, primarily due to a $3.5M drop in mortgage banking activities, while noninterest expense rose 4.0% to $132.6M. Credit quality strengthened with nonperforming assets falling to 0.26% of total assets from 0.58%, and efficiency ratio improved to 62.32%.

• ·Provision for credit losses increased 20.8% YoY to $5.2M in 2025.
• ·Net interest margin expanded to 3.98% from 3.65% YoY.
• ·Common equity tier 1 capital ratio strengthened to 14.45% from 13.53%.
• ·Total risk-based capital ratio slightly declined to 17.26% from 17.86%.
• ·Allowance for credit losses on loans stable at 1.44% of total loans (up from 1.42%).

05-03-2026

Grid Dynamics Holdings, Inc. reported FY2025 revenues of $411.8M, up 17.5% YoY from $350.6M, driven by strong growth in Finance (+66.8% to $100.4M) and Technology, Media & Telecom (+13.0% to $107.5M). However, gross margin declined to 34.6% from 36.2%, Healthcare and Pharma revenues fell 8.3% to $10.2M, Non-GAAP net income decreased 5.6% to $35.1M, and Non-GAAP diluted EPS dropped to $0.40 from $0.47. GAAP net income improved to $9.7M from $4.0M amid ongoing operating losses.

• ·Operating expenses increased 11.7% YoY to $144.2M.
• ·Net cash provided by operating activities was $40.6M in FY2025, down from $30.2M in FY2024 but below $41.1M in FY2023.
• ·Stock-based compensation expense was $30.3M in FY2025.

05-03-2026

Methode Electronics reported net sales of $233.7M for Q3 FY26 (13 weeks ended Jan 31, 2026), down 2.6% from $239.9M in the prior year quarter, and $721.1M for the nine months (39 weeks), down 8.9% from $791.0M (40 weeks). While operating and net losses widened slightly to ($6.1M) and ($15.9M) in Q3 and ($2.1M)/($36.1M) for nine months versus prior year, operating cash flow improved sharply to $33.1M from ($9.0M) over nine months. Total assets remained stable at $1,306.3M with cash rising to $133.7M, though long-term debt increased to $340.7M and shareholders' equity declined to $675.0M.

• ·Selling and administrative expenses Q3 up to $39.1M from $37.7M (+3.7%).
• ·Cash dividends per share reduced to $0.05 in Q3 from $0.14.
• ·Inventories increased to $209.8M from $194.1M QoQ.
• ·Accounts receivable decreased to $215.6M from $241.0M QoQ.

05-03-2026

BridgeBio Oncology Therapeutics reported a widened net loss of $134M in 2025, up 81% YoY from $74M, driven by sharply higher operating expenses including R&D up 66% to $121M and G&A surging 217% to $25M. However, robust financing activities generated $383M in cash inflows from reverse recapitalization and PIPE financing, boosting cash and equivalents to $374M from $31M and flipping stockholders' equity to a positive $411M from a $179M deficit.

• ·Net cash used in operating activities increased to $114M in 2025 from $55M.
• ·Reverse recapitalization and PIPE financing proceeds: $373M net.
• ·Redeemable convertible preferred stock eliminated in 2025 (zero outstanding vs $323M in 2024).
• ·Accrued R&D liabilities rose to $26M from $8M as of Dec 31.
• ·Net loss per share: $(4.30) in 2025 vs $(5,756.41) in 2024.

05-03-2026

Bowman Consulting Group Ltd. reported gross contract revenue of $490M for FY2025, up 14.9% YoY from $427M, with strong segment growth in Natural Resources (+27.2%), Power/Utilities & Energy (+22.7%), and Transportation (+18.2%), though Building Infrastructure grew modestly at 7.4%. Net income rose sharply to $12.8M (2.6% margin) from $3M (0.7% margin), and Adjusted EBITDA increased 22.4% to $72.9M (16.8% margin). However, acquired revenue plunged 79.4% to $8.7M, operating expenses grew to $242M, and revolving credit facility debt more than doubled to $95M from $37M.

• ·Operating income swung to $19.7M profit from $2M loss YoY.
• ·Cash and equivalents increased to $11.1M from $6.7M.
• ·Goodwill rose to $174M from $135M, reflecting acquisitions.
• ·Diluted EPS improved to $0.73 from $0.17.
• ·Total liabilities increased to $319M from $260M.

05-03-2026

Atea Pharmaceuticals narrowed its net loss to $158.3M in 2025 from $168.4M in 2024, a 6% improvement, primarily due to total operating expenses declining 6% to $180.9M, driven by a sharp 33% drop in G&A expenses to $32.9M despite a 3% rise in R&D to $148.0M. However, interest income fell 36% to $16.4M, total assets shrank 32% to $315.2M with marketable securities down 47% to $206.1M, and stockholders' equity decreased 37% to $275.4M following a $25.5M stock repurchase reducing shares outstanding to 78.1M.

• ·Net cash provided by investing activities increased to $188.8M in 2025 from $56.1M in 2024.
• ·Net cash used in financing activities was $25.7M in 2025 versus provided $0.3M in 2024, due to stock repurchase.
• ·Weighted-average shares basic and diluted: 81,495,352 in 2025 vs 84,264,715 in 2024.
• ·Net loss per share improved to $(1.94) from $(2.00).

05-03-2026

Lexicon Pharmaceuticals reported total revenues of $49.8M for FY 2025, up 60% YoY from $31.1M, driven by $45M in licensing revenue (+80% YoY), though net product revenue declined 23% YoY to $4.6M. Net loss narrowed significantly to $50.3M from $200.4M in 2024, with operating expenses dropping 57% to $98.7M; however, cash and equivalents fell to $34.3M from $66.7M, total assets decreased to $185.0M from $298.4M, and stockholders' equity declined to $107.5M from $146.0M.

• ·Long-term debt, net: $49.4M as of Dec 31 2025 (down from $100.3M in 2024 after $48M repayment)
• ·Research and development expenses: $61.1M FY2025 (down 28% YoY from $84.5M)
• ·Selling, general and administrative expenses: $37.3M FY2025 (down 74% YoY from $143.1M)
• ·Stock-based compensation: $12.5M FY2025 (down from $13.5M in 2024)

05-03-2026

Cryoport, Inc. reported total revenue of $176.2M for the year ended December 31, 2025, up 12.4% YoY from $156.8M, with Life Sciences Services growing 17.6% to $96.5M (including BioLogistics up 16.6% and BioStorage/BioServices up 22.2%) while Life Sciences Products increased only 6.6% to $79.7M. Gross margin rose 19.2% to $83.1M, and the company achieved net income of $78.3M versus a $114.8M loss in 2024, driven by $112.3M income from discontinued operations; however, loss from continuing operations narrowed but remained at $34.0M, and Adjusted EBITDA from continuing operations was a $5.8M loss.

• ·Cost of products revenue increased 0.3% YoY to $43.7M.
• ·Selling, general and administrative expenses decreased 6.4% YoY to $102.8M.
• ·No impairment loss in 2025 versus $63.8M in 2024.
• ·Net cash increase of $205.2M in 2025 versus decrease of $1.1M in 2024, driven by $250.3M investing activities.

05-03-2026

AA Mission Acquisition Corp. II, a SPAC, reported its first financials for the period from inception (May 20, 2025) through December 31, 2025, with total assets of $117.2M primarily in a Trust Account of $116.4M from its IPO proceeds. The company generated net income of $585K, driven by $1.1M in Trust Account dividends offsetting a $497K operating loss from general and administrative expenses. No initial business combination has been completed, with shareholders' deficit at $2.4M.

• ·IPO closed with $115M gross proceeds and $3.6M private placement units to Sponsor.
• ·Trust Account shares redemption value at $10.12 per share.
• ·Basic and diluted EPS of $0.08 for both redeemable and non-redeemable shares.
• ·Net cash used in operating activities: $344K; investing: $115.3M; financing provided $116.3M.

05-03-2026

Cherry Hill Mortgage Investment Corp (CHMI) reported net income of $6.9M for the year ended December 31, 2025, down 43% YoY from $12.2M in 2024, with net income applicable to common stockholders swinging to a $3.0M loss from a $2.1M profit amid unrealized losses on derivatives and servicing assets. However, earnings available for distribution (EAD) attributable to common stockholders increased 30% YoY to $15.8M ($0.46 per diluted share from $0.40), supported by net interest income surging to $11.3M from near-zero levels due to lower interest expense. Segment results were mixed, with RMBS comprehensive income rising sharply to $16.9M from $2.1M while Servicing Related Assets declined to $8.8M from $18.6M, and net servicing income fell 6% YoY to $34.0M.

• ·Total expenses decreased 22% YoY to $14.2M from $18.3M.
• ·Accumulated other comprehensive income improved to $3.7M as of Dec 31, 2025 from a $7.3M loss.
• ·Dividends on preferred stock were $9.8M in 2025, slightly down from $10.0M in 2024.
• ·All Other segment showed comprehensive loss of $7.9M in 2025, improved from $13.2M loss in 2024.

05-03-2026

Smith Micro Software reported improved gross margins of 74.1% for FY 2025 (up from 70.2% in 2024) and reduced total operating expenses to 241.1% of revenue (from 310.5%), narrowing the operating loss to 167.1% of revenue and net loss to 168.9% of revenue. However, the company recorded a $63.7% goodwill impairment (down from 116.7% but eliminating all goodwill), resulting in total assets declining to $25.0M from $48.0M and stockholders' equity dropping to $18.4M from $40.8M. Cash burn from operations improved to $7.2M used (from $14.3M), with net cash decrease of $1.3M versus $4.3M prior year.

• ·Accounts receivable declined to $1.8M from $5.7M at Dec 31, 2025 vs 2024.
• ·Selling and marketing expenses improved to 34.4% of revenue from 43.2%.
• ·Research and development expenses decreased to 61.7% of revenue from 68.5%.
• ·General and administrative expenses increased to 57.6% of revenue from 51.5%.
• ·Intangible assets net $18.5M at Dec 31, 2025 vs $24.0M at Dec 31, 2024.

05-03-2026

SandRidge Energy Inc reported total proved reserves of 69.1 MMBoe for 2025, up 9.5% YoY from 63.1 MMBoe, with PV-10 increasing 21.2% to $439.6M; revenues grew 24.8% YoY to $156.4M driven by natural gas sales (+94.4%). However, net interest income fell sharply to $3.7M from $7.7M due to lower interest income, production taxes rose 45.2% to $9.8M, and DD&A for oil/gas increased 40.3% to $36.4M.

• ·Mid-Continent reserves/production ratio of 10.2 years and weighted average economic reserve life of 35.0 years.
• ·Lease operating expenses per Boe improved to $5.35 from $6.61, but production taxes per Boe rose to $1.45 from $1.12.
• ·General and administrative expenses increased to $13.2M from $11.7M.

05-03-2026

Adial Pharmaceuticals reported a reduced net loss of $7.98M for the year ended December 31, 2025, compared to $13.20M in 2024, primarily due to lower R&D expenses ($2.62M, down 19% YoY) and absence of $4.46M inducement expense. However, G&A expenses rose slightly by 2% to $5.18M, total operating expenses declined modestly to $7.80M, and significant share dilution occurred with common shares outstanding increasing over 4x to 1.11M. Cash and equivalents grew 57% to $5.88M, bolstered by $8.47M in financing activities, though operating cash use remained high at $6.49M.

• ·Total assets increased to $6.67M as of Dec 31 2025 from $5.04M as of Dec 31 2024.
• ·Equity method investment declined to $0.49M from $0.98M.
• ·Net cash used in operating activities improved slightly to $6.49M from $6.92M.
• ·Weighted average shares outstanding increased to 668,630 from 194,059; loss per share improved to $(11.93) from $(68.01).

05-03-2026

Monroe Capital Corp (MRCC) reported a challenging 2025 with total investment income declining 37.5% YoY to $37.9M from $60.5M in 2024, net investment income dropping 53.5% to $11.4M, and a net decrease in net assets from operations of $5.1M versus a $9.7M increase in 2024. While operating expenses fell 26.2% YoY to $26.2M and no incentive fees were incurred, NAV per share eroded to $7.68 by Q4 2025 from $8.85 in Q4 2024, with shares trading at deepening discounts to NAV up to (23.2)% in Q4. Distributions were reduced to $0.18 in Q4 2025 from $0.25 quarterly in prior periods.

• ·Interest income declined to $26.2M in 2025 from $44.3M in 2024 (-40.8% YoY).
• ·PIK interest income fell to $7.7M in 2025 from $9.2M in 2024 (-16.5% YoY).
• ·Average stated interest rate on debt improved to 6.2% in 2025 from 6.8% in 2024.
• ·Largest portfolio company investment in SLF: $4.9M; total five largest: $23.9M (Dec 31, 2024).

05-03-2026

Inuvo, Inc. reported FY2025 net revenue of $86.2M, up 2.9% YoY from $83.8M, with marketing costs declining 13.0% to $51.9M and total operating expenses down 8.2% to $70.9M. However, gross profit fell 10.5% to $64.2M due to an 82.8% surge in cost of revenue to $22.0M, operating cash flow turned negative at ($1.8M) from positive $0.23M, total assets shrank to $24.9M from $32.2M, and stockholders' equity decreased to $10.0M from $13.5M.

• ·Net cash used in operating activities FY2025: ($1.8M) vs. provided $0.23M FY2024.
• ·Net cash used in investing activities FY2025: ($1.6M) vs. ($1.9M) FY2024.
• ·Net cash provided by financing activities FY2025: $3.8M vs. used ($0.35M) FY2024.
• ·Allowance for credit losses: $99K (2025) vs. $145K (2024).
• ·Accumulated deficit: ($178.3M) as of Dec 31, 2025 vs. ($173.2M) Dec 31, 2024.

05-03-2026

CarParts.com, Inc. reported FY ended January 3, 2026 (53 weeks) net sales of $547.5M, down 7.0% from $588.8M in FY ended December 28, 2024 (52 weeks), with gross profit declining 8.8% to $179.3M and gross margin contracting 60 basis points to 32.8%. Net loss widened to $50.4M from $40.6M, EBITDA deteriorated to -$28.6M from -$21.5M, and Adjusted EBITDA fell to -$14.0M from -$7.1M. Operating cash flow swung to a use of $34.1M from generation of $10.3M, contributing to a $10.6M net decrease in cash.

• ·Operating expenses increased to 41.7% of net sales from 40.3%.
• ·Stock compensation expense decreased to $8.1M from $12.0M.
• ·Workforce transition costs: $1.5M (2026) vs $0.6M (2024).
• ·Impairment of long-lived assets: $3.7M in 2026.
• ·Recent agreements include Purchase Agreement dated Sep 8, 2025 with International Auto Parts (Cayman) Limited et al., and First Amendment to Credit Agreement dated Sep 8, 2025.

05-03-2026

For the year ended December 31, 2025, PREFORMED LINE PRODUCTS CO (PLPC) reported net sales of $669.3M, up 13% YoY from $593.7M (+$75.6M), driven by PLP-USA (+17%) and The Americas (+24% excluding currency translation). Gross profit increased 10% to $208.5M, and operating income rose to $55.1M from $50.8M; however, net income attributable to shareholders declined 5% to $35.3M from $37.1M (-$1.8M), with sharp drops in international segments including The Americas (-37%), EMEA (-33%), and Asia-Pacific (-24%). Total assets grew to $653.6M from $573.9M, supported by higher cash ($83.4M) and inventories ($148.7M), though other expenses surged.

• ·Foreign currency translation positively impacted consolidated net sales by $1.4M in FY2025.
• ·Goodwill of $30.7M at Dec 31, 2025, with $17.0M attributable to EMEA reporting unit; no impairment recognized.
• ·Long-term debt increased to $32.9M (less current portion) from $18.4M YoY.
• ·Accumulated other comprehensive loss improved to $(53.4M) from $(82.9M).

05-03-2026

Stabilis Solutions, Inc. reported FY 2025 total revenues of $68.2M, down 6.9% YoY from $73.3M, driven by a 6.1M gallon drop in LNG deliveries, rental revenues declining 26.5% to $5.3M, service revenues falling 32.5% to $5.0M, and other revenues dropping 45.9% to $0.7M, though partially offset by higher natural gas prices adding $3.9M. Operating expenses rose 1.2% to $70.8M amid higher SG&A (+12.1%), resulting in an operating loss of $1.3M versus a $5.0M profit in 2024. The company posted a net loss of $1.4M compared to a $4.6M profit YoY.

• ·Revenue declines included $4.9M from reduced rental/service/other due to lower equipment needs and contract conclusions.
• ·Unfavorable customer mix reduced revenues by $0.9M YoY.
• ·Cost of revenues decreased $2.4M from lower LNG volume and $2.2M from reduced rental/service costs (travel/labor).

05-03-2026

CIMG Inc. reported net revenues of $15.8M for the three months ended December 31, 2025, up dramatically over 68,900% YoY from $23K, with gross profit rising to $89K from $15K, fueled by sales to concentrated customers including ZNF (76% of revenue). However, a $17.5M fair value variation loss drove a net loss attributable to CIMG of $19.5M, wider than the prior year's $1.5M loss, with operating expenses up 35% to $2.0M, cash burn from operations at $8.5M, and ending cash of just $45K.

• ·Customer concentration risk: ZNF accounted for 76% of Q3 FY26 revenues; ZHXY 7.5%.
• ·Reverse stock split adjustments applied retroactively to prior periods.
• ·Proceeds from stock issuances and warrants totaled ~$29.4M in Q3 FY26 vs ~$3.9M prior year.
• ·Accounts receivable increased by $1.3M; inventories up $11.9M; digital assets down $24.5M.
• ·Basic and diluted loss per share: ($1.43) vs ($0.17) YoY.

05-03-2026

TaskUs reported service revenue growth of 19.0% YoY to $1.18B for FY 2025, driven by strong performance in AI Services (+58.6%), Trust & Safety (+23.9%), and Rest of World (+36.4%), while Digital Customer Experience grew modestly at 8.2%. Net income surged 123.0% to $102M with operating income up 52.2%, but Free Cash Flow declined to $74M from $100M and Adjusted EBITDA margin was nearly flat at 21.0% versus 21.1%. Headcount expanded to approximately 65,500 from 59,000, and net revenue retention improved to 113% from 102%.

• ·GAAP diluted EPS increased to $1.10 from $0.50; Adjusted EPS to $1.63 from $1.29.
• ·Net revenue retention rate improved to 113% from 102%.
• ·Purchase of property and equipment rose to $63.5M from $39.1M.

05-03-2026

Via Renewables, Inc. reported total revenues of $463.5M for FY 2025, up 16% YoY from $398.9M in 2024, driven by 58% higher natural gas volumes, while Adjusted EBITDA rose 23% to $72.3M and Retail Gross Margin increased 6% to $149.8M with strong natural gas segment growth (+27% to $60.8M). However, net income declined 42% to $35.6M from $61.1M amid higher depreciation/amortization and operating expenses, Retail Electricity Gross Margin fell 5% to $88.9M, cash from operations dropped 17% to $42.1M, and RCE attrition worsened to 4.2%.

• ·Electricity volumes sold increased 9.0% YoY in 2025 vs 2024.
• ·Natural gas volumes sold surged 58.4% YoY in 2025 vs 2024.
• ·Customer acquisition costs rose to $10.4M in 2025 from $9.5M in 2024.
• ·Distributions/dividends paid increased to $30.3M in 2025 from $10.7M in 2024.
• ·Non-POR Credit Loss as % of Revenue improved to 0.5% in 2025 from 1.3% in 2024.